Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emtricitabine + tenofovir alafenamide
- Development stage
- Approved
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Emtricitabine + tenofovir alafenamide (F/TAF), marketed under the brand name Descovy, is a fixed-dose combination of two antiretroviral agents used for the treatment and prevention of HIV infection. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI), and tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI). Both components function by inhibiting the HIV reverse transcriptase enzyme, which is essential for viral replication, leading to DNA chain termination. Developed by Gilead Sciences, this formulation is evaluated for its improved safety profile, particularly regarding bone and renal toxicity, compared to the older tenofovir disoproxil fumarate (TDF) formulation. In a specific clinical context led by Eastern Virginia Medical School, F/TAF is being studied in Phase II trials to assess its acceptability and adherence for HIV pre-exposure prophylaxis (PrEP) among adolescent girls and young women in Africa.
- Brand names
- Descovy
- Other names
- emtricitabine/tenofovir alafenamide
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseHIV-2 reverse transcriptase
Beyond the preview
Go deeper on emtricitabine + tenofovir alafenamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emtricitabine + tenofovir alafenamide.